RecruitingPhase 2NCT06822946

Zhibitai Capsules for the Treatment of Primary Hyperlipidemia

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chengdu Diao Jiuhong Pharmaceutical Factory
Intervention
zhibitai capsule(drug)
Enrollment
192 enrolled
Eligibility
18-75 years · All sexes
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06822946 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials